GlassScriptPhysician profile
Carolyn Kollar
NPI 1487833695
$2,386.83
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $1,149 · 2023: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579 · Consulting Fee: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.45 |
| Consulting Fee | $262.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $566.23 | 2022-2023 | |
| Amgen INC. | $533.20 | 2021-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $275.86 | 2022-2023 | Xarelto |
| Abbvie INC. | $262.50 | 2023 | |
| Pfizer INC. | $162.61 | 2022-2023 | |
| Medtronic, INC. | $129.89 | 2021 | |
| Novo Nordisk INC | $125.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $107.69 | 2022-2023 | |
| Bard Peripheral Vascular, INC. | $87.63 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $44.06 | 2021-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $40.86 | 2021-2022 | |
| Edwards Lifesciences Corporation | $25.11 | 2021 | |
| Merck Sharp & Dohme LLC | $15.71 | 2023 | Verquvo |
| Elutia, INC. | $10.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Kollar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.